have altered our practice. The media scares following publication of the first reports from the WHI and MWS led to hormone replacement therapy (HRT) being considered a risky treatment. In 2007, it appears that we have come full circle. He hopes that now the messages coming out about HRT will be more consistent and allow both patients and prescribers more confidence to know where, when and how to prescribe appropriately.
Medical litigation is always a fear. Dedicated services for peri-and postmenopausal women are being developed at primary and secondary care levels. As in other areas of clinical activity, unintended harm to patients may occur. Leroy Edozien concludes that risk management should be incorporated in the development of a dedicated menopause service.
Ovarian cancer has a high mortality as it is diagnosed late. The most promising prospect for its early detection comes from the rapidly advancing field of clinical proteomics. However, Koehn and Oehler find that, although very promising, major technical challenges are still preventing new discoveries in ovarian cancer proteomics from being translated into clinical practice.
Lower urinary tract symptoms trouble over a third of women. Nicholas Christofi and Andrew Hextall examine lifestyle, behavioural, physical and complementary interventions that have been introduced with a view to relieve lower urinary tract symptoms. They conclude that many lack a solid evidence base as regards their efficacy and few have been subjected to robust randomized trials.
Cardiovascular disease is the most common cause of death in women but some of the challenges of management differ from those with men. Wasing Taggu and Guy Lloyd address the gender-specific issues of cardiovascular management, with emphasis on ischaemic heart disease and coronary risk factor modification. They conclude that ischaemic heart disease presents later in women than men, who are therefore older and more likely to suffer from co-morbidities such as diabetes and hypertension and these factors may explain much of the variability in response to treatment.
Grape flavonoids are polyphenols and epidemiological evidence from Mediterranean countries suggests that dietary polyphenols are of benefit to health and reduce the incidence of cardiovascular disease. Indeed, in the 15 countries that constituted the European Union up to 2004, women's life expectancy was highest in France, at 84 years. Alyson Huntley concludes that the evidence is promising for the benefit of grape flavonoids in the form of red wine, red grape juice and related preparations for cardiovascular risk factors.
Falls among older people are common and their occurrence is associated with detrimental effects on physical and psychosocial functioning, and they increase the risk of fracture. However, falls are not an inevitable consequence of ageing and there is growing evidence of effective interventions to prevent them. Rob Morris examines accurate screening methods to identify high-risk populations, which are important if interventions are to be cost-effective.
The British Menopause Society Council has produced a consensus statement on estrogen-and non-estrogen-based treatments for the prevention and treatment of osteoporosis. It is a practical guide to the subject.
The issue is concluded with a personal view by John Studd on suppression of cyclical ovarian function in the treatment of severe premenstrual syndrome, the literature review by John McGarry and the news section by Simon Brown.
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